Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 7
Submit an article Journal homepage
184
Views
5
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission

Wei-Yang LiJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, PR China; ;Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China; ;Suzhou Institute of Blood and Marrow Transplantation, Suzhou, PR China
,
Ying WangJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, PR China; ;Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China; ;Suzhou Institute of Blood and Marrow Transplantation, Suzhou, PR China
,
Su-Ning ChenJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, PR China; ;Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China; ;Suzhou Institute of Blood and Marrow Transplantation, Suzhou, PR China
,
Hui-Ying QiuJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, PR China; ;Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China; ;Suzhou Institute of Blood and Marrow Transplantation, Suzhou, PR China
,
Zheng-Zheng FuJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, PR China; ;Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China; ;Suzhou Institute of Blood and Marrow Transplantation, Suzhou, PR China
,
De-Pei WuJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, PR China; ;Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China; ;Suzhou Institute of Blood and Marrow Transplantation, Suzhou, PR China
&
Ai-Ning SunJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, PR China; ;Collaborative Innovation Center of Hematology, Soochow University, Suzhou, PR China; ;Suzhou Institute of Blood and Marrow Transplantation, Suzhou, PR ChinaCorrespondence[email protected]
 show all
Pages 1652-1658 | Received 23 Aug 2017, Accepted 01 Oct 2017, Published online: 18 Oct 2017
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

This retrospective study tested the feasibility of decitabine (DAC) plus intermediate-dose cytarabine (ID-AraC) followed by HLA-mismatched granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral donor blood stem cells (GPBSCs) infusion as consolidation treatment for older patients with acute myeloid leukemia (AML) in first complete remission (CR). A total of 23 patients received this regimen for 3 cycles (D-GPBSCs group), and the outcome was compared with that of 19 patients treated with repeated cycles of ID-AraC chemotherapy (chemo group). The two regimens were well tolerated. The median recovery times for neutrophils and platelets were shorter in D-GPBSCs group than in chemo group (p<.05). No graft-versus-host disease (GVHD) was observed in D-GPBSCs group. The 2-year leukemia-free survival (LFS) and overall survival (OS) were better in D-GPBSCs group (51.6 and 55.4%) than in chemo group (27.1 and 34.2%) (p = .047 and p = .056). These data suggest that DAC and ID-AraC followed by GPBSCs as a consolidation regimen may be a safe and promising option for older patients with AML.

Acknowledgments

The authors would like to thank all the physicians, nurses, and support personnel (Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University) for their dedicated care of the patients in this study. We thank Dr. Wan Zhu (Foreign Languages Department of Soochow University) for assistance in editing the article. This study was supported by the National Natural Science Foundation of China [81570138], the National Key Research and Development Program [2016YFC0902800].

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1390235.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.